Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (SHA: 603392)

Beijing Wantai Biological Pharmacy Enterprise Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	3,001	3,819	5,193	1,416	710.67	283.99
Short-Term Investments	450	400	-	200	52.54	5
Trading Asset Securities	2,166	2,055	2,009	40.39	50.36	58
Cash & Short-Term Investments	5,618	6,274	7,201	1,656	813.57	346.99
Cash Growth	-6.88%	-12.88%	334.83%	103.56%	134.46%	-18.81%
Accounts Receivable	2,617	2,999	3,960	2,277	711.6	261.39
Other Receivables	57.12	48.71	5.15	12.45	13.04	0.5
Receivables	2,679	3,053	3,970	2,292	724.64	264.02
Inventory	832.35	905.48	869.14	593.17	400.04	236.43
Prepaid Expenses	-	-	-	-	-	0.16
Other Current Assets	69.96	69.42	139.4	105.2	39.54	38.05
Total Current Assets	9,199	10,302	12,180	4,647	1,978	885.66
Property, Plant & Equipment	3,174	2,641	2,235	1,703	790.98	627.7
Long-Term Investments	1,302	1,432	911.3	61.3	211.3	228.5
Other Intangible Assets	519.84	507.24	289.37	289.92	226.66	232.67
Long-Term Deferred Tax Assets	185.03	157.95	66.01	68.97	56.49	93.69
Long-Term Deferred Charges	240.06	215.33	175.49	27.18	27.76	27.05
Other Long-Term Assets	343.17	459.41	372.3	249.09	212.7	69.65
Total Assets	14,962	15,715	16,230	7,046	3,504	2,165
Accounts Payable	202.49	234.28	275.47	154.08	107.29	85.05
Accrued Expenses	1,172	1,653	2,572	1,541	440.8	147.66
Short-Term Debt	86.35	81.14	140.14	235.64	77.66	-
Current Portion of Long-Term Debt	21.99	87.19	3.07	-	-	-
Current Portion of Leases	7.87	13.3	13.73	13.93	-	-
Current Income Taxes Payable	3.21	7.49	99.02	146.55	4.37	7.84
Current Unearned Revenue	42	70.38	82.28	70.3	40.92	-
Other Current Liabilities	516.19	523.42	299.34	204.64	157.98	251.48
Total Current Liabilities	2,052	2,670	3,485	2,366	829.03	492.03
Long-Term Debt	130.47	115.36	102.49	4.9	-	21
Long-Term Leases	10.78	12.36	18.43	32.59	-	-
Long-Term Unearned Revenue	33.36	33.65	41.37	76.44	94.26	71.16
Long-Term Deferred Tax Liabilities	-	-	17.15	-	-	-
Other Long-Term Liabilities	-	-	-	3.8	-	-
Total Liabilities	2,226	2,831	3,665	2,483	923.29	584.19
Common Stock	1,268	1,268	906.07	607.04	433.6	390
Additional Paid-In Capital	3,336	3,312	3,729	445.83	446.27	172.02
Retained Earnings	8,105	8,250	7,906	3,413	1,674	996.8
Treasury Stock	-158.56	-129.42	-200.17	-	-	-
Total Common Equity	12,551	12,701	12,341	4,466	2,554	1,559
Minority Interest	185.41	183.06	223.63	96.2	26.73	21.91
Shareholders' Equity	12,736	12,884	12,565	4,562	2,580	1,581
Total Liabilities & Equity	14,962	15,715	16,230	7,046	3,504	2,165
Total Debt	257.46	309.35	277.86	287.06	77.66	21
Net Cash (Debt)	5,360	5,965	6,923	1,369	735.91	325.99
Net Cash Growth	-6.87%	-13.85%	405.71%	86.03%	125.74%	-19.78%
Net Cash Per Share	4.30	4.73	5.54	1.11	0.62	0.30
Filing Date Shares Outstanding	1,224	1,268	1,268	1,232	1,232	1,108
Total Common Shares Outstanding	1,224	1,268	1,268	1,232	1,232	1,108
Working Capital	7,147	7,632	8,695	2,281	1,149	393.63
Book Value Per Share	10.26	10.01	9.73	3.62	2.07	1.41
Tangible Book Value	12,031	12,193	12,052	4,176	2,327	1,326
Tangible Book Value Per Share	9.83	9.61	9.50	3.39	1.89	1.20
Buildings	726.79	724.87	628.89	392.67	253.3	246.27
Machinery	1,586	1,510	1,185	666.87	565.97	490.03
Construction In Progress	1,381	814.56	720.51	924.38	231.5	81.68

Source: S&P Capital IQ. Standard template. Financial Sources.